Back |
home / stock / tsha / tsha message board
Subject | By | Source | When |
---|---|---|---|
Guess the float just got locked and MMs | KOmani | investorshub | 10/25/2022 3:57:28 PM |
TSHA is the top % Gainer in the | MiamiGent | investorshub | 10/25/2022 3:33:19 PM |
Yea! I agree with you 100% | subslover | investorshub | 10/25/2022 1:06:05 PM |
Yea! I agree with you 100% | subslover | investorshub | 10/25/2022 1:06:04 PM |
Just as I post this it seems like | KOmani | investorshub | 10/25/2022 12:13:44 PM |
Doesn't this imply $7ish per share value? | KOmani | investorshub | 10/25/2022 12:09:56 PM |
Astellas and Taysha Gene Therapies Announce Strategic Investment | subslover | investorshub | 10/25/2022 9:22:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10 15 total vg) with dosing...
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it...
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support t...